Donepezil
Treatment for Lewy Body Dementia
Typical Dosage: 5-10 mg daily
Effectiveness
70%
Safety Score
60%
Clinical Trials
10
Participants
5.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
5-10 mg daily
Time to Effect
4-12 weeks
Treatment Duration
lifetime
Evidence Quality
MODERATENumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
12(Treat 12 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$75
Monitoring:$750
Side Effect Mgmt:$150
Total Annual:$975
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$9,750/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$2,786
Donepezil Outcomes
for Lewy Body Dementia
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+35%
Common Side Effects
Nausea
+15%
Diarrhea
+10%
Vomiting
+8%
Insomnia
+7%
Muscle cramps
+3%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
8 completed trials for Donepezil in Lewy Body Dementia
A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)
NCT02345213COMPLETEDPHASE4
160 participants
INTERVENTIONAL
Saitama, Japan
Started: Mar 1, 2015
A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431)
NCT00543855COMPLETEDPHASE2
167 participants
INTERVENTIONAL
Nagoya, Japan +42 more
Started: Nov 1, 2007
A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies
NCT00598650COMPLETEDPHASE2
160 participants
INTERVENTIONAL
Started: Feb 1, 2008
Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB)
NCT00776347COMPLETEDNA
24 participants
INTERVENTIONAL
Suita, Japan
Started: Oct 1, 2008
A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase
NCT01278407COMPLETEDPHASE3
142 participants
INTERVENTIONAL
Anjo-shi, Japan +55 more
Started: Feb 1, 2011
Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies (DLB).
NCT02448784COMPLETED
591 participants
OBSERVATIONAL
Tokyo, Japan
Started: Apr 20, 2015
A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease
NCT01944436COMPLETED
57 participants
OBSERVATIONAL
Toronto, Canada
Started: Sep 1, 2006
Monitoring Anti-Dementia Drugs by Serum Levels
NCT04117178COMPLETEDPHASE4
132 participants
INTERVENTIONAL
Roskilde, Denmark
Started: Feb 4, 2020